Status:
RECRUITING
Clinical and Radiographic Success of MTA vs Biodentine
Lead Sponsor:
Geisinger Clinic
Conditions:
Indirect Pulp Cap
Pulpotomy
Eligibility:
All Genders
2-12 years
Phase:
PHASE4
Brief Summary
The purpose of this prospective study is to compare the clinical and radiographic success of MTA and Biodentine as a medicament in vital pulp therapy in maxillary and mandibular primary molars in a pe...
Detailed Description
This is a interventional randomized split mouth prospective study that evaluates the clinical and radiographic success of mineral trioxide aggregate (MTA) and Biodentine as pulpotomy and indirect pulp...
Eligibility Criteria
Inclusion
- Male or female patients ages of 2 to ≤12 years.
- Bilateral symptomatic or asymptomatic vital primary molars with caries approximating or into the pulp.
- Patient who need a pulpotomy and/or indirect pulp cap treatments in two or more quadrants.
- Parents of patients who can provide consent in English.
- Patients who need treatment in an operating room setting at Geisinger.
Exclusion
- Pre-operative radiographic or clinical symptoms associated with irreversible pulpitis or necrotic pulp.
- Radiographs not displaying furcation region of the tooth.
- Patients with cardiac conditions who need prophylaxis for infective Endocarditis.
- Patients with any type of cancer in the past or present.
- Non-restorable molars.
Key Trial Info
Start Date :
November 12 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
646 Patients enrolled
Trial Details
Trial ID
NCT04863222
Start Date
November 12 2021
End Date
December 1 2026
Last Update
December 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Geisinger
Danville, Pennsylvania, United States, 17822